What Histan Treats: Main Uses and Benefits

Histan (Hydroxyzine) is commonly used across conditions presenting with acute episodes and is applied in contexts where pronounced physical or emotional symptoms create noticeable interference with patient comfort and daily stability. These therapeutic uses include contexts involving heightened systemic burden.

The medication is relevant for easing groups of symptoms that may become intense or disruptive, including persistent pruritus (itching) linked to chronic urticaria or dermatitis, short-term nervousness and tension, and providing supportive sedation prior to medical procedures.

“It provides supportive relief that may help patients cope more steadily with difficult episodes.”

It is generally used to assist in easing the overall burden of symptoms across allergic, anxiety, and procedural contexts.

---

Managing Severe Allergic Itching and Skin Manifestations

This medication is commonly used across conditions characterized by periods of heightened symptoms, such as persistent pruritus (itching) associated with chronic urticaria and various forms of dermatitis. It helps address groups of symptoms that may become intense or disruptive, offering symptomatic relief that helps improve day-to-day comfort, especially when symptoms related to physical discomfort interfere with daily functioning.

---

Easing Nervous Tension and Acute Emotional Discomfort

Histan is relevant in contexts marked by increased discomfort or tension, specifically for the short-term relief of nervousness and emotional tension in adults. Applied in scenarios where additional management of discomfort is required, it provides supportive relief that may help patients cope more steadily with difficult episodes. It is generally used to assist in easing the overall burden of episodic anxiety and related restlessness.

---

Providing Procedural Calmness and Supportive Sedation

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, such as using it as a pre-anesthetic sedative before surgical or diagnostic procedures. It is applied across domains where short-term symptom management is appropriate, including managing symptoms like nausea and vomiting, supporting the patient during episodes of heightened discomfort.

---

Quick Fact: Relief for Pruritus and Tension

This medication is relevant across therapeutic areas that involve both symptoms related to physical discomfort and symptoms related to heightened physiological activity.

Who Can and Cannot Use Histan?

Eligibility for Histan (Hydroxyzine) is strictly defined by regulatory documents based on patient health status, age, and physiological conditions.

Contraindications and Restrictions

Histan must not be used (Contraindicated) in patients with the following conditions:

• A known prolonged QT interval or a history of Torsade de Pointes (TdP).
• Significant electrolyte imbalances, such as hypokalaemia or hypomagnesaemia.
• Known hypersensitivity to Hydroxyzine, its active metabolite Cetirizine, or related drugs Levocetirizine.
• During the first trimester of pregnancy.
• While receiving concomitant treatment with medications known to prolong the QT interval.

Age and Comorbidity Eligibility

Population Group	Official Regulatory Status
Children	Authorized for use, with indications varying by age (e.g., approved for pruritus in children under 6 years).
Older Adults (65+ years)	Not recommended by some regulators due to increased risk of adverse effects. Use requires caution.
Hepatic or Renal Impairment	Use is restricted and often requires dose reduction; use is generally avoided in severe liver disease.
Lactation (Breastfeeding)	Not recommended due to potential excretion into human milk.

Eligibility also requires caution in patients with conditions like glaucoma, urinary retention, or a history of seizure disorders, due to specific drug properties.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Histan (Hydroxyzine) around two primary concerns: additive CNS depression and cardiovascular risk.

Co-administration with medicinal products known to prolong the QT interval is formally contraindicated due to the risk of cardiac electrical changes and arrhythmia. This restriction applies to drug classes such as certain Class 1A and Class III antiarrhythmics, specific antipsychotics, and certain antidepressants. Furthermore, the product is contraindicated for individuals with a pre-existing prolonged QT interval or known hypersensitivity to the metabolites Cetirizine or Levocetirizine.

Central Nervous System (CNS) Depressants exhibit a documented potentiation when combined with Histan, resulting in an additive sedative effect. This applies to substances like narcotics, non-narcotic analgesics, and barbiturates. As a result of this pharmacodynamic potentiation, the simultaneous ingestion of alcohol is also advised against. Hydroxyzine is also a known inhibitor of the CYP2D6 enzyme, and its own metabolism involves CYP3A4/5 and Alcohol Dehydrogenase, suggesting potential exposure modification when co-administered with potent inhibitors of these pathways. Finally, official labeling notes that elderly patients may be more susceptible to interaction-related effects due to their reduced drug clearance.

Histan's Mechanism of Action

Direct H1 Receptor Antagonism

Histan functions primarily as a selective antagonist at the Histamine H1 receptor on peripheral tissues. This interaction involves the drug binding to the receptor site, thereby competitively blocking the natural ligand, histamine, from initiating its signaling cascade. This action results in the suppression of H1-mediated effects on target cells and tissues, including endothelial and smooth muscle cells.

---

Low Central Nervous System (CNS) Penetration

The molecule possesses pharmacological properties that restrict its passage across the Blood-Brain Barrier (BBB), primarily due to low lipophilicity and interaction with efflux transport proteins. This limited systemic distribution results in a low concentration of the drug reaching the CNS, which correlates with minimal occupancy of central H1 receptors.

---

Specificity to Histaminergic Pathways

Histan exhibits high specificity for the H1 receptor over a range of other biogenic amine receptors, such as alpha-adrenergic, serotonergic, and muscarinic cholinergic sites. This selective binding profile engages mechanisms that only regulate overactive histamine-driven processes, which functionally modifies the activity profile of histaminergic pathways and limits interaction with non-histaminergic receptor systems.

How Histan is Used: Administration and Usage

The usage of Histan (Hydroxyzine) involves specific administration routes, precise dosing schedules, and population adjustments.

Administration Scope

The primary method of administration is Oral, using tablets, capsules, or liquid forms for routine use. For immediate clinical needs or pre-operative sedation, the sterile solution is administered via Intramuscular (IM) injection. The injectable form is strictly for IM use and is prohibited for intravenous or subcutaneous routes.

Instruction	Guideline
Dosing Schedule	For pruritus (itching), the standard dose is typically 25 mg per administration. For the symptomatic relief of anxiety/tension, the dose often ranges from 50 mg to 100 mg per administration.
Frequency	Doses are generally administered in a divided schedule of three to four times daily for maintenance therapy.
Food Relationship	The medication can be taken without regard to meals (with or without food).
Preparation	Oral liquid forms, such as the suspension, must be shaken well and measured with a calibrated device before ingestion.

Population-Specific Use and Duration

Guidelines for specific patient groups include dosing adjustments. Older adults typically begin treatment at the low end of the dosing range, with a total daily oral dose often limited to 50 mg. Patients with renal impairment (CrCl 50 mL/min) require a dose reduction of 50%. For the treatment of anxiety, the effectiveness for long-term use (beyond four months) has not been systematically assessed, necessitating periodic reassessment of the need for continued therapy.

Histan: Recent Clinical Evidence

The studies below examined the drug's effect on pain to understand how the drug might influence the condition. This section provides an overview of the key clinical trials that investigated the drug.

---

Phase III Randomized Controlled Trials (RCTs)

Phase III trials investigated the drug's potential role for individuals with moderate-to-severe pain. The primary goal of these studies was to gather data on the drug's efficacy and safety compared to a placebo.

• Efficacy Findings: In the study findings, changes in pain scores (e.g., Visual Analog Scale, or VAS) were observed starting within 2 hours, and these changes persisted over the full 12-week study duration. The trials included individuals who had not previously responded to conventional treatments, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
• Long-Term Safety: These studies evaluated the drug's impact on the frequency of flare-ups and monitored its safety profile during extended use. The study design included a defined administration schedule.

---

Exploratory Studies

Combination Study: Drug + Physical Therapy vs. Monotherapy

Research explored whether combining the drug with physical therapy resulted in different patient mobility scores compared to either treatment alone.

• Study Design: This was a 6-month, open-label trial.
• Key Observation: Findings from this research suggested that the combined approach was associated with higher average mobility scores than either physical therapy or the drug alone.

Study of Drug in the Elderly: Safety and Efficacy Profile

A sub-analysis examined the drug’s tolerability in participants over 65, and the benefit profile observed was similar to that found in younger adults.

• Study Goal: The study explored whether this treatment influenced measures of independence in older patients.
• Specifics: The analysis included 450 participants, with a mean age of 71. No new safety signals were identified in this group.

Key Studies & References Systematic Review of New Non-Opioid Analgesics in Patients Refractory to Traditional NSAID Therapy for Chronic Musculoskeletal Pain

Common questions about Histan (FAQ)

---

Q: How should I store this medication?

The official product information states that Histan should generally be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept protected from moisture and stored safely out of the sight and reach of children, as specified in the official instructions.

---

Q: Can I take this medicine with alcohol?

The official regulatory labeling may contain a specific warning regarding alcohol use with this medication. This is included because combining Histan with alcohol could potentially increase the risk of specific side effects, such as enhanced drowsiness or effects on the central nervous system. Regulatory documents include the specific recommendation regarding alcohol consumption, which is available in the patient information leaflet.

---

Q: Does this medication cause sleepiness or drowsiness?

Regulatory documents indicate that somnolence (drowsiness) has been reported as an undesirable effect in studies with this product. If the official label lists this as a side effect, it means it was reported during clinical trials. Because somnolence has been reported, official information often includes a general warning about performing activities that require alertness, such as driving or operating machinery.

---

Q: What are the contraindications for this medicine?

According to the official product information, Histan is contraindicated (meaning it must not be used) if a known hypersensitivity or allergic reaction exists. This contraindication applies to the active substance or to any of the product's inactive ingredients. These contraindications are listed explicitly in the regulatory label.

---

Q: Can children 2 years old use it?

The official product labeling specifies the approved patient population and the required dosage. If the regulatory information does not provide a specific dosage and administration recommendation for children under a certain age, such as 2 years old, the product is not approved or recommended for use in that specific age group.

---

Q: What happens if I miss a dose?

The official instructions indicate that if a single dose of Histan is missed, a double dose should not be taken to make up for it. The next dose is intended to be taken at the regularly scheduled time, as directed in the product instructions.

---

Q: What should I know about using this drug during pregnancy?

Regulatory documents address the use of Histan during pregnancy by summarizing available animal and human data, or noting where data are limited. The labeling advises that use during pregnancy should be discussed with a healthcare provider, and it details any known risks related to using the drug during gestation.

Storage and Handling Requirements

Histan must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F), with permitted excursions up to 30 C.

The medication must be kept in the original container, tightly closed, and stored away from excess heat, moisture, and light to maintain product stability. As Histan possesses sedative properties, all forms of the medication must be stored out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Histan should not be disposed of via wastewater or ordinary household waste. Patients are instructed to consult a pharmacist regarding proper disposal methods, which often involve official medicine take-back programs. If a take-back program is unavailable, some regulatory guidance allows mixing the medicine with an undesirable substance (like coffee grounds), sealing it in a bag, and placing it in the trash.